Breaking News

Bavarian Nordic Acquires Travel Vaccines from Emergent Biosolutions

The acquisition adds two revenue-generating vaccines for the prevention of cholera and typhoid fever.

Bavarian Nordic announced has entered into an agreement with Emergent BioSolutions, to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus for a price tag of up to $380 million, including $270 million in an upfront payment and up to $110 million in future conditional milestone payments. The acquisition also includes facilities and key personnel related to t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters